This is the second resubmission of an application for a Midcareer Investigator Award in Patient-Oriented Research (K24) in response to PA-00-005 focused in the areas of Child Psychiatry/Pediatric Psychopharmacology and Addictive Disorders. The overall objectives of the applicant are to a) increase the candidate's knowledge in completing clinical trials in adolescents with substance use disorders (SUD, including drug or alcohol abuse or dependence), b) heighten his involvement in training and mentoring, and 3) complete a five year prospective study of the efficacy of atomoxetine (ATMX) in the treatment of adolescents with Attention- Deficit/Hyperactivity Disorder (ADHD) plus SUD. This Award would also provide an opportunity to develop a well-integrated Center for the diagnosis and treatment of adolescent SUD integrated seamlessly into the pediatric psychopharmacology clinic at the Massachusetts General Hospital (MGH). Substance use disorders constitute one of the most feared outcomes and difficult to manage clinical problems in adolescents with ADHD. High rates of ADHD have been reported in adolescents with SUD. Conversely, untreated ADHD is a risk factor for the development of SUD. Despite this bi-directional overlap, little data are available to guide clinicians in the treatment of ADHD plus SUD in adolescents. ATMX, a recently approved norepinephrine reuptake inhibitor, has been shown to be effective in the treatment of ADHD; however, ATMX remains untested in individuals with SUD.
The aim of this research proposal is to evaluate prospectively the efficacy of ATMX in adolescents with ADHD plus SUD. We plan to evaluate systematically adolescents with ADHD plus SUD, treat all of these adolescents with six courses of cognitive behavioral therapy, and randomize youth equally to receive ATMX or placebo. We will evaluate outcome in multiple domains including ADHD, SUD, other psychopathology, and safety parameters throughout the twelve-week trial. In this way, we will follow current clinical guidelines of addressing the SUD prior to ADHD; while accruing valuable information as to the efficacy of a novel non-stimulant medication in treating ADHD, as well as the effects on SUD and functional outcome. This investigation will provide the research template for the five-year award providing an excellent foundation for the applicant to further his own knowledge. Through offsite collaborative efforts, the candidate plans to develop specific skills related to the integration of psycho-social (particularly cognitive-behavioral therapy) and psychopharmacological trials in adolescent SUD trials, and methodological and conceptual issues in the testing of compounds for SUD in adolescents with SUD. The Award would also provide the opportunity for the candidate to expand roles in mentoring residents, Child Psychiatry Fellows, and junior faculty on complementary methodology within Child Psychiatry/Pediatric psychopharmacology and the Addictions. Through didactic seminars, supervision, individual and group meetings, and involvement in ongoing research studies - including the proposed research project - the applicant proposes to systematically mentor individuals at all levels of their training and professional careers in the overlap fields of Child Psychiatry/Pediatric Psychopharmacology and SUD. It is anticipated that trainees will develop skills necessary to further develop their careers independently, thus providing future researchers in a vastly underrepresented area in the fields of Child Psychiatry and Addictions. In this manner, the candidate will satisfy overall career development and mentoring objectives of the K24 award.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
5K24DA016264-04
Application #
7284840
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Montoya, Ivan
Project Start
2004-09-28
Project End
2009-07-31
Budget Start
2007-08-01
Budget End
2008-07-31
Support Year
4
Fiscal Year
2007
Total Cost
$180,360
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Biederman, Joseph; Fitzgerald, Maura; Woodworth, K Yvonne et al. (2018) Does the course of manic symptoms in pediatric bipolar disorder impact the course of conduct disorder? Findings from four prospective datasets. J Affect Disord 238:244-249
Wilens, Timothy E; Carrellas, Nicholas W; Martelon, MaryKate et al. (2017) Neuropsychological functioning in college students who misuse prescription stimulants. Am J Addict 26:379-387
Wilens, Timothy; Zulauf, Courtney; Martelon, MaryKate et al. (2016) Nonmedical Stimulant Use in College Students: Association With Attention-Deficit/Hyperactivity Disorder and Other Disorders. J Clin Psychiatry 77:940-7
Pedrelli, Paola; Nyer, Maren; Yeung, Albert et al. (2015) College Students: Mental Health Problems and Treatment Considerations. Acad Psychiatry 39:503-11
Wilens, Timothy E; Rosenbaum, Jerrold F (2013) Transitional aged youth: a new frontier in child and adolescent psychiatry. J Am Acad Child Adolesc Psychiatry 52:887-90
Wilens, Timothy E; Martelon, MaryKate; Anderson, Jesse P et al. (2013) Difficulties in emotional regulation and substance use disorders: a controlled family study of bipolar adolescents. Drug Alcohol Depend 132:114-21
Wilens, Timothy E; Morrison, Nicholas R (2012) Substance-use disorders in adolescents and adults with ADHD: focus on treatment. Neuropsychiatry (London) 2:301-312
Martelon, Marykate; Wilens, Timothy E; Anderson, Jesse P et al. (2012) Are obstetrical, perinatal, and infantile difficulties associated with pediatric bipolar disorder? Bipolar Disord 14:507-14
Wilens, Timothy E; Martelon, Marykate; Joshi, Gagan et al. (2011) Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. J Am Acad Child Adolesc Psychiatry 50:543-53
Wilens, Timothy E; Gault, Laura M; Childress, Ann et al. (2011) Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. J Am Acad Child Adolesc Psychiatry 50:73-84.e1

Showing the most recent 10 out of 46 publications